MedTrace Logo

Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

NCT01326364 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2016-07-01

No results posted yet for this study

Summary

The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.

Conditions

Interventions

PROCEDURE

Stereotactic body radiotherapy

Standard of Care

DRUG

Iodixanol

IV, calculated per patient

DRUG

Iohexol

IV, Calculated per patient

Sponsors & Collaborators

Principal Investigators

  • Aya Kamaya · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01326364 on ClinicalTrials.gov